ESR1 and cancer: For patients with a biopsied metastatic lesion, we noted there was no change in PFS regardless of the Ki67 value, or the change from initial cancer, although patients with estrogen receptors <90% in metastatic lesion exhibited worse PFS (HR 1.9, 95% CI 1.0–3.7, p = 0.02).